Table 3a. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data
Last Updated: April 21, 2021
|
Table 3a. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data
|
|
|---|---|
References
- Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of bamlanivimab and etesevimab. 2021. Available at: https://www.fda.gov/media/145802/download.
- Dougan M, Nirula A, Gottlieb RL, et al. Bamlanivimab+etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Presented at: Conference on Retroviruses and Opportunistic Infections. 2021. Virtual. Available at: https://www.croiconference.org/wp-content/uploads/sites/2/resources/2021/vCROI-2021-Abstract-eBook.pdf.
- Regeneron. COV-2067 Phase 3 trial in high-risk outpatients shows that REGEN-COV (2400 mg and 1200 mg IV doses) significantly reduces risk of hospitalization or death while also shortening symptom duration. 2021. Available at: https://newsroom.regeneron.com/index.php/static-files/a7173b5a-28f3-45d4-bede-b97370bd03f8. Accessed April 5, 2021.
- Phase 3 trial shows REGEN-COV (casirivimab with imdevimab) antibody cocktail reduced hospitalization or death by 70% in non-hospitalized COVID-19 patients. News release. Regeneron. 2021. Available at: https://investor.regeneron.com/news-releases/news-release-details/phase-3-trial-shows-regen-covtm-casirivimab-imdevimab-antibody. Accessed April 5, 2021.
- Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of casirivimab and imdevimab. 2020. Available at: https://www.fda.gov/media/143892/download.
- Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N Engl J Med. 2020. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33332778.